The Cure Score is our editorial framework for ranking T1D cure-research programs against public evidence — not a scientific instrument, not a prediction, and not a guarantee. This is how we build it, and where its limits are.
Every tracked program is scored 0–100 internally against these six weights. The precise number is never published — see the publishing rule below.
Where a program's internal score places it.
Score 90–100
Score 80–89
Score 70–79
Score 60–69
No score assigned — usually preclinical with no public efficacy data yet
How proven a claim is — independent of how well the program ranks.
Published in a journal.
Press release or investor relations — not yet peer-reviewed.
An FDA or ClinicalTrials.gov filing.
No human data yet.
A second, independent tag — clinical maturity is a different question from evidence tier (source credibility).
"Cured of Type 1 diabetes" is one of the most misused headlines in this field. A durable cure needs all three finish-line criteria at once — most reported results clear one.
Improves glucose control — insulin still required as before.
Changes progression or preserves remaining beta-cell function.
Little or no insulin needed, but an ongoing requirement remains — typically immunosuppression.
No external insulin, durable regulation, no immunosuppression. Nothing we track has cleared this yet.
In order of trust, for every claim we publish.
This is our editorial ranking, built from public evidence — not a prediction or guarantee. It changes as new evidence comes in.
See tracked programs